 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 November 1995 | Volume 123 Issue 9 | Pages 649-655
Objective: To determine the effectiveness of aspirin in preventing ischemic events in patients with asymptomatic carotid stenosis.
Design: Double-blind, placebo-controlled trial.
Setting: University-affiliated hospitals.
Patients: 372 neurologically asymptomatic patients with carotid stenosis of 50% or more in at least one artery as determined by luminal diameter reduction on duplex ultrasonography.
Intervention: Patients were randomly assigned to receive either enteric coated aspirin, 325 mg/d, or identically appearing placebo. Duration of therapy was 2.0 years for the aspirin recipients and 1.9 years for the placebo recipients.
Outcome Measures: Patients were scheduled for a clinical examination every 6 months for assessment of the occurrence of any clinical event in the composite end point, which consisted of transient ischemic attack, stroke, myocardial infarction, unstable angina, or death.
Results: At baseline, the 188 patients receiving aspirin and the 184 patients receiving placebo had similar demographic, ultrasonographic, and laboratory characteristics. The median duration of follow-up was 2.3 years. The annual rate of all ischemic events and death from any cause was 12.3% for the placebo group and 11.0% for the aspirin group (P = 0.61). The Cox proportional-hazards analysis yielded an adjusted hazard ratio (aspirin-placebo) of 0.99 (95% CI, 0.67 to 1.46; P = 0.95). The annual rates for vascular events only were 11% for the placebo group and 10.7% for the aspirin group (P = 0.99). The multivariate analysis yielded a hazard ratio of 1.08 (CI, 0.72 to 1.62; P = 0.71).
Conclusion: Aspirin did not have a significant long-term protective effect in asymptomatic patients with high-grade (
*For members of the Asymptomatic Cervical Bruit Study Group and participating institutions, see the Appendix.
Author and Article Information
From the Montreal General Hospital, Montreal, Quebec, Canada.
ARTICLE
Lack of Effect of Aspirin in Asymptomatic Patients with Carotid Bruits and Substantial Carotid Narrowing
50%) carotid stenosis.
Acknowledgments: The authors thank Merck Frosst Canada for providing the study medication and Ms. S. Lavigne for secretarial support.
Grant Support: By the National Health and Research Development Program, Health Canada.
Requests for Reprints: Robert Cote, MD, Division of Neurology, Montreal General Hospital, 1650 Cedar Avenue, Montreal H3G 1A4, Quebec, Canada.
Current Author Addresses: Dr. Cote and Ms. Bourque: Montreal General Hospital, Division of Neurology, 1650 Cedar Avenue, Montreal H3G 1 A4, Quebec, Canada.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  M. Sobel and R. Verhaeghe Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 815S - 843S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Paciaroni, V Caso, M Acciarresi, R W Baumgartner, and G Agnelli Management of asymptomatic carotid stenosis in patients undergoing general and vascular surgical procedures J. Neurol. Neurosurg. Psychiatry, October 1, 2005; 76(10): 1332 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Gorelick and S. M. Weisman Risk of Hemorrhagic Stroke With Aspirin Use: An Update Stroke, August 1, 2005; 36(8): 1801 - 1807. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Clagett, M. Sobel, M. R. Jackson, G. Y. H. Lip, M. Tangelder, and R. Verhaeghe Antithrombotic Therapy in Peripheral Arterial Occlusive Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 609S - 626S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Straus, S. R. Majumdar, and F. A. McAlister New Evidence for Stroke Prevention: Scientific Review JAMA, September 18, 2002; 288(11): 1388 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Jackson and G. P. Clagett Antithrombotic Therapy in Peripheral Arterial Occlusive Disease Chest, January 1, 2001; 119(1_suppl): 283S - 299S. [Full Text] [PDF]
|
|
|
|
|
|
R. Cote, C. Wolfson, S. Solymoss, A. Mackey, J. R Leclerc, D. Simard, F. Rouah, F. Bourque, and B. Leger Hemostatic Markers in Patients at Risk of Cerebral Ischemia Stroke, August 1, 2000; 31(8): 1856 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Awtry and J. Loscalzo Aspirin Circulation, March 14, 2000; 101(10): 1206 - 1218. [Full Text] [PDF]
|
|
|
|
 |
|
 M. H Liang, M. Corzillius, S.-C. Bae, P. Fortin, J. M Esdaile, and M. Abrahamowicz A conceptual framework for clinical trials in SLE and other multisystem diseases Lupus, October 1, 1999; 8(8): 570 - 580. [PDF]
|
|
|
|
|
|
J. He, P. K. Whelton, B. Vu, and M. J. Klag Aspirin and Risk of Hemorrhagic Stroke: A Meta-analysis of Randomized Controlled Trials JAMA, December 9, 1998; 280(22): 1930 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Hart and M. J.G. Harrison Aspirin Wars : The Optimal Dose of Aspirin to Prevent Stroke Stroke, April 1, 1996; 27(4): 585 - 587. [Full Text]
|
|
|
|
|
|
H.J.M. Barnett, M. Kaste, H. Meldrum, and M. Eliasziw Aspirin Dose in Stroke Prevention : Beautiful Hypotheses Slain by Ugly Facts Stroke, April 1, 1996; 27(4): 588 - 592. [Full Text]
|
|
|
|
 |
|
 ASPIRIN AND ASYMPTOMATIC CAROTID BRUITS Journal Watch (General), November 7, 1995; 1995(1107): 1 - 1. [Full Text]
|
|
Article
